Randomized Trial of Patiromer on Efficacy to Reduce Episodic Hyperkalemia in Patients with ESKD Treated With Hemodialysis

Introduction: Individuals with end-stage kidney disease (ESKD) maintained on hemodialysis (HD) carry a high risk of cardiac arrhythmias. This risk is heightened by episodic hyperkalemia. The purpose of the study was to investigate whether patiromer administered daily reduced episodes of hyperkalemia...

Full description

Saved in:
Bibliographic Details
Main Authors: John P. Middleton, Shifeng Sun, Susan Murray, Clemontina A. Davenport, James P. Daubert
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:Kidney International Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024924018771
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items